- Home
- LOAN vs MAIA Comparison
LOAN vs MAIA Comparison
Compare LOAN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- MAIA
- Stock Information
- Founded
- LOAN 1989
- MAIA 2018
- Country
- LOAN United States
- MAIA United States
- Employees
- LOAN N/A
- MAIA N/A
- Industry
- LOAN Real Estate Investment Trusts
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- MAIA Health Care
- Exchange
- LOAN Nasdaq
- MAIA Nasdaq
- Market Cap
- LOAN 64.4M
- MAIA 65.9M
- IPO Year
- LOAN 1999
- MAIA 2022
- Fundamental
- Price
- LOAN $5.32
- MAIA $2.26
- Analyst Decision
- LOAN
- MAIA
- Analyst Count
- LOAN 0
- MAIA 0
- Target Price
- LOAN N/A
- MAIA N/A
- AVG Volume (30 Days)
- LOAN 13.3K
- MAIA 192.4K
- Earning Date
- LOAN 10-23-2024
- MAIA 11-12-2024
- Dividend Yield
- LOAN 8.65%
- MAIA N/A
- EPS Growth
- LOAN 6.53
- MAIA N/A
- EPS
- LOAN 0.49
- MAIA N/A
- Revenue
- LOAN $7,394,068.00
- MAIA N/A
- Revenue This Year
- LOAN N/A
- MAIA N/A
- Revenue Next Year
- LOAN N/A
- MAIA N/A
- P/E Ratio
- LOAN $10.86
- MAIA N/A
- Revenue Growth
- LOAN 5.79
- MAIA N/A
- 52 Week Low
- LOAN $4.27
- MAIA $0.82
- 52 Week High
- LOAN $5.90
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- LOAN 43.98
- MAIA 37.99
- Support Level
- LOAN $5.32
- MAIA $2.42
- Resistance Level
- LOAN $5.50
- MAIA $3.48
- Average True Range (ATR)
- LOAN 0.08
- MAIA 0.31
- MACD
- LOAN -0.01
- MAIA -0.07
- Stochastic Oscillator
- LOAN 15.63
- MAIA 27.08
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.